目的 探索0.05%环孢素A联合奥洛他定滴眼液治疗过敏性结膜炎相关干眼的疗效。方法 选取广西壮族自治区人民医院2022年8月-2023年4月过敏性结膜炎相关干眼患者63例63眼，按数字表法随机分为对照组（n = 33）和观察组（n = 30），对照组患者给予0.1%盐酸奥洛他定滴眼液和0.3%玻璃酸钠滴眼液，观察组给予0.1%盐酸奥洛他定滴眼液和0.05%环孢素A滴眼液，分别评估两组患者治疗前后的眼表疾病指数（OSDI）、眼部症状总评分（TOSS）、结膜充血评分、结膜乳头和滤泡评分、泪液分泌试验（SIT）、泪河高度（TMH）、睑板腺分泌能力评分、睑板腺分泌物性质评分、睑板腺缺失面积评分、角膜荧光素染色（CFS）、泪膜破裂时间（BUT）、非侵入性首次泪膜破裂时间（NIBUTf）、非侵入性平均泪膜破裂时间（NIBUTav）和治疗期间药物安全性。结果 治疗3个月后观察组患者的症状（OSDI、TOSS评分）和体征（结膜充血评分、结膜乳头和滤泡评分、SIT、睑板腺分泌物性质评分、CFS、BUT、NIBUTf、NIBUTav）较对照组显著改善，差异有统计学意义（P < 0.05）。两组患者的TMH、睑板腺分泌能力评分、睑板腺缺失面积评分比较差异无统计学意义（P > 0.05）。治疗期间两组患者均无局部或全身不良反应。结论 0.05%环孢素A联合奥洛他定滴眼液治疗可显著改善过敏性结膜炎相关干眼患者眼红、眼痒、异物感等眼部不适症状，增加泪液分泌，提高泪膜稳定性，且安全性好。

Objective To explore the efficacy of 0.05% cyclosporine A combined with olopatadine eye drops to treat patients with dry eye disease associated with allergic conjunctivitis. Methods 63 patients (63 eyes) with dry eye disease associated with allergic conjunctivitis in the People’s Hospital of Guangxi Zhuang Autonomous Region from August 2022 to April 2023 were enrolled and randomly divided into control group (n = 33) and observation group (n = 30). The patients of control group used 0.1% olopatadine eye drops and 0.3% sodium hyaluronate eye drops, while the observation group used 0.1% olopatadine eye drops and 0.05% cyclosporine A eye drops. The ocular surface disease index(OSDI), total ocular symptom score(TOSS), conjunctival congestion score, conjunctival papillae and follicle score, Schirmer I test (SIT), tear meniscus height (TMH), meibomian gland secretion ability and property score, meibomian gland loss area score, corneal fluorescein staining (CFS), tear film break-up time (BUT), noninvasive first tear film break-up time (NIBUTf), noninvasive average tear film break-up time (NIBUTav) before and after treatment and the drug safety during the treatment period were evaluated. Results After 3 months of treatment, the symptoms (OSDI, TOSS) and signs (conjunctival congestion score, conjunctival papillae and follicle score, SIT, meibomian gland secretion property score, CFS, BUT, NIBUTf, NIBUTav) of the observation group patients were significantly improved compared with those in the control group, and the differences were statistically significant (P < 0.05). There were no statistically significant differences in the TMH, meibomian gland secretion ability score, and meibomian gland loss area score between the two groups(P > 0.05). During the treatment period, there were no local or systemic adverse reactions. Conclusion The combined use of 0.05% cyclosporine A and olopatadine eye drops can significantly improve ocular discomfort symptoms of patients with dry eye disease associated with allergic conjunctivitis, such as red eyes, itchy eyes and foreign body sensation, increase tear secretion, promote tear film stability and have high safety.

广西壮族自治区卫生健康委员会自筹经费科研课题（Z-A20230133）；广西眼科疾病临床医学研究中心（编号：桂科AD19245193 ）